Long-term Health Risks of Peptide Use

What long-term means here

Long-term risk means effects that show up after months or years of repeated use. It doesn't cover the flushing or nausea people notice in the first week. For most peptides sold for research use, nobody has measured it. Where human safety data exist, they usually span days to weeks. The longest controlled data come from two compounds that went through drug development: tesamorelin, a prescription medicine with 52 weeks of trial data on its label, and MK-677, an oral non-peptide secretagogue tested for 2 years in older adults.

When a vendor page says a peptide has no reported long-term side effects, it usually means nobody looked. This page covers the risks that are documented or plausible for each class. For weighing those risks against possible benefits, see our risk-and-reward framework for long-term use; for data quality compound by compound, see long-term health outcomes by compound.

How long the human data run

Ipamorelin's human record is thinner still. FDA's compounding review cites serious adverse events, death among them, in a study of intravenous ipamorelin for gut motility. The agency says it has no safety information for other injectable routes.

Growth hormone secretagogues: glucose and IGF-1

GH secretagogues such as ipamorelin and MK-677, and GHRH analogs such as CJC-1295 and tesamorelin, push the pituitary to release more growth hormone. The liver responds by making more IGF-1. Two long-term concerns follow, and they differ a lot in how well they're documented.

Blood sugar: measured in trials

Growth hormone works against insulin, and the longer trials show it. In the 2-year MK-677 trial, where healthy adults aged 60-81 took 25 mg by mouth daily, fasting glucose rose by about 5 mg/dL on average and insulin sensitivity fell. Tesamorelin's label, based on trials of 2 mg daily in adults with HIV-associated lipodystrophy, reports HbA1c of 6.5% or higher in 5% of participants versus 1% on placebo, a hazard ratio of 3.3 for developing diabetes. These are the best-documented long-term effects in the class, and they come from randomized trials rather than reasoning about mechanism.

IGF-1 and cancer: plausible, not measured

IGF-1 drives cell growth, which is why the cancer question keeps coming up. Tesamorelin's label gives the clearest numbers: after 26 weeks, 47% of trial participants had IGF-1 above 2 standard deviation scores (roughly the upper limit of normal) and 36% were above 3. Among people who stayed on it for 52 weeks, those figures were 34% and 23%. The label says "the effects of prolonged elevations in IGF-1 levels are unknown." It rules out use in people with active cancer and states that long-term cardiovascular safety hasn't been established.

The usual human model is acromegaly, where a pituitary tumor keeps GH and IGF-1 high for years. A 2018 Danish cohort study with a meta-analysis of 23 studies found overall cancer rates about 1.5 times the general population's, with higher ratios for colorectal (2.6) and thyroid cancer (9.2). The authors' own nationwide cohort found a smaller, non-significant rise (1.1) and suggested some earlier single-center studies overstated the risk. Acromegaly involves far higher IGF-1 for far longer than a course of peptides, so it's an upper bound rather than a stand-in. No study has tracked cancer rates in people using secretagogues.

Heart failure and other signals

A Phase IIb trial of MK-677 in 123 older adults recovering from hip fracture was stopped early for a congestive heart failure signal in a small number of patients, and FDA cites it in keeping ibutamoren in Category 2 for compounding. Whether that applies to younger, healthier users is disputed. For CJC-1295, FDA lists increased heart rate and systemic vasodilatory reactions and calls the clinical data limited; the 2006 trials ran 49 days at most. Sermorelin's 6-week trial in older men found no significant adverse effects but also no change in IGF-1, so it says little about sustained exposure.

Users who post lab results on forums often describe IGF-1 near the top of the reference range and creeping fasting glucose on tesamorelin or on CJC-1295 with ipamorelin, which matches the trial data. Many cycle these compounds to limit exposure, but no study has tested whether peptide cycling strategies lower long-term risk.

Melanotan II: moles and melanoma

Melanotan II stimulates pigment cells across the body, not only in sun-exposed skin. A 2017 review in the International Journal of Dermatology described growing numbers of case reports of darkening moles and new atypical (dysplastic) moles in melanotan users. It counted four reports of melanoma arising from existing moles during or shortly after use, while noting that conclusive evidence of a causal link was lacking. FDA's compounding review cites case reports of melanoma and priapism, along with posterior reversible encephalopathy syndrome (PRES) and sympathomimetic toxidrome.

Newer reports keep appearing. In 2025, UK surgeons described oral mucosal melanoma in a 22-year-old woman who had used a melanotan II nasal spray for tanning. A 2026 case report described five melanomas in situ in one patient who had also used tanning beds and anabolic hormones. That overlap runs through the literature, since many melanotan users also seek out sun or sunbeds. Case reports can't establish cause, but a steady run of similar ones is a signal, not reassurance.

There's also a monitoring problem. Catching melanoma early depends on noticing a mole that changes, and a drug that darkens many moles at once makes that harder for users and dermatologists alike. No cohort study has followed melanotan users over years.

BPC-157 and TB-500: no long-term data

BPC-157

The site rates BPC-157's evidence as emerging, meaning consistent animal data and very little human data. A 2025 systematic review in HSS Journal found 36 studies, 35 of them preclinical. Animal safety studies in rats and dogs found no toxicity across a wide dose range, but none followed the animals past 6 weeks, and the authors found no clinical safety data in humans. A 2025 pilot gave 2 adults IV infusions of 10 mg and then 20 mg on consecutive days and reported no side effects or biomarker changes. A 2025 narrative review counted only three small, uncontrolled human pilots in total.

None of this shows long-term safety. Six weeks in animals and two days in two people can't speak to months of use, and users commonly describe multi-week courses, sometimes repeated, that outlast anything studied. The absence of reported harm reflects an absence of follow-up.

The main theoretical concern is angiogenesis. Animal and cell studies show BPC-157 boosting VEGFR2 signaling and new blood vessel growth. That helps healing and could in principle feed a tumor. The same narrative review points to preclinical work in which BPC-157 instead counteracted VEGF-driven tumor growth. Neither direction has been tested in people.

TB-500

TB-500 is often described as a synthetic version of thymosin beta-4, but that isn't accurate. Anti-doping chemists who analyzed the product identified Ac-LKKTETQ, an acetylated 7-amino-acid fragment (residues 17-23) of the 43-amino-acid thymosin beta-4 protein. As of October 2026, FDA says it has not identified any human exposure data for this fragment. Human trials of full-length thymosin beta-4, such as eye-drop studies, tested a different molecule and don't carry over. The site rates TB-500's evidence as preliminary.

So the long-term risk of TB-500 isn't low; it's unknown. Users add their own layer of uncertainty, since many aren't sure whether a vial labeled TB-500 holds the fragment or the full protein.

The product itself

For gray-market peptides generally, product quality is a risk that adds up with repeated use. The HSS Journal review lists unregulated manufacturing and contamination as possible sources of harm alongside unknown clinical safety. Our guide to peptide sourcing and quality control covers what third-party testing can and can't tell you.

What we still don't know

• No registry or cohort follows peptide users for years, so cancer and cardiovascular outcomes in the people who actually use these compounds are unmeasured.
• Whether the glucose and IGF-1 changes seen in older adults and in people with HIV lipodystrophy look the same in younger, leaner users hasn't been tested.
• As of October 2026, a small randomized University of Arkansas pilot of BPC-157 after rotator cuff surgery, with daily subcutaneous injections for 90 days, is listed as not yet recruiting, with a planned start in January 2027. If it runs, it would be the longest controlled human exposure to BPC-157 so far.